SpyGlass Pharma Names Anand Sundaram As Vice President, Head of Commercial To Lead Commercial Team, Launch Strategies, And Market Readiness For Late-Stage Drug Delivery Platform Entering Two Phase III Trials

SpyGlass Pharma, a late-stage biopharmaceutical company, announced the appointment of Anand Sundaram as the company’s Vice President and Head of Commercial. In this role, Sundaram will be responsible for building and managing the company’s commercial organization, developing launch strategies, and overseeing preparations for the potential commercialization of SpyGlass’s late-stage drug delivery platform. The company is currently progressing this platform into two Phase III clinical trials, marking a critical stage in its development and positioning it for potential market entry.

Sundaram brings more than a decade of experience in successfully launching ophthalmic treatments and other high-impact therapeutics. His expertise spans pre-commercial planning, patient access programs, reimbursement strategy, payer engagement, and marketing. His track record demonstrates a consistent ability to deliver results in competitive healthcare markets and guide innovative treatments from clinical development to successful commercial introduction.

Most recently, Sundaram served as Vice President of Marketing at OPTHEA, an Australian ophthalmology company, where he oversaw the launch readiness team and directed marketing strategy for sozinibercept, a therapy designed for wet age-related macular degeneration. His leadership there ensured the company was well-positioned to enter a highly specialized and competitive market. Prior to OPTHEA, Sundaram held a senior role at Iveric Bio as Executive Director of Access and Reimbursement. In that position, he led early commercial planning for IZERVAY (avacincaptad pegol), a treatment for geographic atrophy, and continued to manage access and reimbursement efforts through the first year after Iveric Bio was acquired by Astellas Pharma in a $5.9 billion deal.

Patrick Mooney, Chief Executive Officer of SpyGlass Pharma, stated, “We are excited to welcome Anand to SpyGlass Pharma as we advance our innovative SpyGlass Drug Delivery Platform into two Phase III trials. Anand’s deep expertise in commercial strategy and the reimbursement landscape will be instrumental in shaping our plans for a successful launch.”

Mr. Sundaram, mentioned, “I am honored to join SpyGlass at such a pivotal moment for a company poised to revolutionize the delivery of ophthalmic drugs. The Company’s sustained drug delivery technology represents a breakthrough solution for patients with glaucoma or ocular hypertension by addressing non-adherence to topical treatments—a key driver of disease progression and eventual vision loss. I look forward to working with SpyGlass leadership to build a strong commercial strategy and team and advancing the company’s vision to help patients see drop-free.”

Earlier in his career, Sundaram held leadership roles at Novartis, where he contributed to the launch of BEOVU and led marketing initiatives for ENTRESTO, two key therapies in their respective markets. At Genentech, he successfully managed the launch of the LUCENTIS pre-filled syringe, further strengthening his experience in ophthalmology and innovative drug delivery systems. Sundaram holds bachelor’s degrees in biomedical engineering and economics from Duke University. His appointment underscores SpyGlass Pharma’s commitment to building a strong commercial infrastructure as it moves closer to bringing its advanced ophthalmic therapies to patients.